Q2 FY2022 · Earnings release
July 28, 2022 · 14 pages
Read Alnylam Pharmaceuticals, Inc.'s results firsthand
Preview the first 2 pages of this earnings release
Create a free account to start reading
Full documents are included with Professional
Alnylam Pharmaceuticals, Inc.
165.00
USD
-9.00
(-5.17%)
Alnylam Pharmaceuticals, Inc. Documents
Q2 FY2022 documents
Earnings release
14 pages
Jul 28, 2022
Quarterly report
76 pages
Presentation
Alnylam Pharmaceuticals Inc. - Special Call (4)
35 pages
Presentation
Alnylam Pharmaceuticals Inc - Q2 2022 - Conference Call Deck
29 pages
Presentation
Alnylam Pharmaceuticals Inc. - Special Call (5)
25 pages
Press release
Alnylam Pharmaceuticals Press Release _ Aug 03, 2022 _ Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloi
4 pages
Press release
Alnylam Pharmaceuticals Press Release _ Sep 08, 2022 _ Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidos
4 pages